Profile data is unavailable for this security.
About the company
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). Its other clinical programs include Fimepinostat and CA-170. Fimepinostat is an oral, dual inhibitor of histone deacetylase (HDAC), and phosphotidyl-inositol 3 kinase (PI3K) enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target V-domain Ig Suppressor of T-cell Activation (VISTA) and PDL1 immune checkpoint proteins.
- Revenue in USD (TTM)9.81m
- Net income in USD-47.73m
- Incorporated2000
- Employees48.00
- LocationCuris Inc128 Spring Street, 4 Maguire RoadLEXINGTON 02421United StatesUSA
- Phone+1 (617) 503-6500
- Fax+1 (617) 503-6501
- Websitehttps://www.curis.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
VolitionRX Ltd | 797.03k | -34.91m | 58.45m | 110.00 | -- | -- | -- | 73.33 | -0.4603 | -0.4603 | 0.0104 | -0.1901 | 0.0425 | -- | 6.32 | 7,245.73 | -188.25 | -111.92 | -- | -196.20 | -- | -- | -4,425.95 | -10,793.31 | -- | -173.85 | -- | -- | 153.04 | -- | -16.68 | -- | 29.13 | -- |
AN2 Therapeutics Inc | 0.00 | -66.03m | 59.36m | 41.00 | -- | 0.5365 | -- | -- | -2.59 | -2.59 | 0.00 | 3.71 | 0.00 | -- | -- | 0.00 | -62.19 | -- | -68.38 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -51.33 | -- | -- | -- |
LAVA Therapeutics NV | 12.54m | -28.59m | 59.41m | 37.00 | -- | 1.17 | -- | 4.74 | -1.07 | -1.07 | 0.4668 | 1.93 | 0.107 | -- | 9.09 | 338,837.80 | -24.40 | -- | -28.91 | -- | 79.64 | -- | -228.02 | -- | -- | -- | 0.108 | -- | -65.09 | -- | -31.55 | -- | -- | -- |
Turnstone Biologics Corp | 0.00 | -74.92m | 60.37m | 82.00 | -- | 0.7545 | -- | -- | -3.53 | -3.53 | 0.00 | 3.46 | 0.00 | -- | -- | 0.00 | -80.25 | -- | -94.45 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -73.66 | -- | -78.05 | -- | -- | -- |
Enzo Biochem Inc | 32.80m | -23.31m | 60.96m | 179.00 | -- | 0.8489 | -- | 1.86 | -0.4699 | 0.6708 | 0.6586 | 1.40 | 0.3738 | 1.61 | 4.10 | 183,257.00 | -26.56 | -12.21 | -39.50 | -15.79 | 42.17 | 37.09 | -71.07 | -18.76 | 2.89 | -- | 0.0476 | -- | -4.85 | -21.01 | -23.02 | -- | 7.89 | -- |
Calcimedica Inc | 0.00 | -14.94m | 61.05m | 14.00 | -- | 3.54 | -- | -- | -2.64 | -2.64 | 0.00 | 1.61 | 0.00 | -- | -- | 0.00 | -48.34 | -63.99 | -66.59 | -72.71 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 3.51 | -- | -44.35 | -- |
Curis Inc | 9.81m | -47.73m | 61.06m | 48.00 | -- | 6.45 | -- | 6.22 | -8.68 | -8.68 | 1.77 | 1.61 | 0.1253 | -- | 4.39 | 204,416.70 | -60.97 | -37.25 | -69.58 | -41.12 | 97.60 | 96.05 | -486.45 | -409.44 | -- | -- | 0.00 | -- | -1.37 | -0.7891 | 16.34 | -- | -- | -- |
Regencell Bioscience Holdings Ltd | 0.00 | -7.45m | 61.16m | 12.00 | -- | 3.58 | -- | -- | -0.5863 | -0.5863 | 0.00 | 1.31 | 0.00 | -- | -- | 0.00 | -82.73 | -- | -113.11 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 21.15 | -- | -- | -- |
Champions Oncology Inc | 49.22m | -9.73m | 61.58m | 230.00 | -- | -- | -- | 1.25 | -0.7183 | -0.7183 | 3.64 | -0.1514 | 1.56 | -- | 6.17 | 214,017.40 | -30.91 | -5.40 | -96.45 | -11.88 | 40.09 | 47.96 | -19.76 | -3.09 | -- | -- | -- | -- | 9.69 | 21.63 | -1,073.54 | -- | 18.50 | -- |
Aeon Biopharma Inc | 0.00 | -485.01m | 61.81m | 10.00 | -- | -- | -- | -- | -13.04 | -13.04 | 0.00 | -5.20 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -27.67 | -- | -- | -- | -- | -631.85 | -- | -- | -- |
RetinalGenix Technologies Inc | 0.00 | -3.73m | 62.51m | 0.00 | -- | -- | -- | -- | -0.2124 | -0.2124 | 0.00 | -0.085 | 0.00 | -- | -- | -- | -12,800.17 | -9,163.75 | -- | -- | -- | -- | -- | -- | -- | -969.35 | -- | -- | -- | -- | 46.58 | -- | -- | -- |
Earth Science Tech Inc | 5.98m | 330.94k | 62.97m | 8.00 | 208.33 | 29.17 | 118.98 | 10.52 | 0.001 | 0.001 | 0.0195 | 0.0069 | 3.16 | 11.41 | 106.07 | 747,970.00 | 17.50 | -224.84 | 42.70 | -- | 62.29 | 37.79 | 5.53 | -333.58 | 0.386 | -0.3899 | 0.1023 | -- | 243.77 | -36.31 | -111.95 | -- | -- | -- |
enVVeno Medical Corp | 0.00 | -22.12m | 63.58m | 31.00 | -- | 1.50 | -- | -- | -1.70 | -1.70 | 0.00 | 3.18 | 0.00 | -- | -- | 0.00 | -54.31 | -58.43 | -56.14 | -62.76 | -- | -- | -- | -260,799.30 | -- | -- | 0.00 | -- | -- | -- | 4.67 | -- | 21.58 | -- |
Dyadic International Inc | 2.26m | -7.85m | 63.74m | 7.00 | -- | 14.09 | -- | 28.26 | -0.2724 | -0.2724 | 0.0783 | 0.1547 | 0.1769 | -- | 4.51 | 322,197.20 | -61.58 | -36.82 | -73.50 | -39.85 | 38.24 | 22.47 | -348.00 | -410.16 | -- | -- | 0.5634 | -- | -1.07 | 17.48 | 30.20 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Maverick Capital Ltd.as of 31 Mar 2024 | 582.27k | 9.88% |
M28 Capital Management LPas of 31 Mar 2024 | 421.95k | 7.16% |
Kingdon Capital Management LLCas of 04 Apr 2024 | 345.73k | 5.87% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 217.03k | 3.68% |
CM Management LLCas of 31 Mar 2024 | 120.00k | 2.04% |
Citigroup Global Markets, Inc. (Investment Management)as of 31 Mar 2024 | 91.87k | 1.56% |
Renaissance Technologies LLCas of 31 Mar 2024 | 91.56k | 1.55% |
Geode Capital Management LLCas of 31 Mar 2024 | 62.30k | 1.06% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 53.48k | 0.91% |
Focused Wealth Management, Inc.as of 31 Mar 2024 | 33.16k | 0.56% |